Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis

被引:31
|
作者
Xie, Tong [1 ]
Zhang, Zhening [1 ]
Zhang, Xiaotian [1 ]
Qi, Changsong [1 ]
Shen, Lin [1 ]
Peng, Zhi [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
中国国家自然科学基金;
关键词
immunotherapy; chemotherapy; PD-L1; cutoff value; gastric cancer; EFFICACY; SAFETY; COMBINATION; NIVOLUMAB; CHEMO;
D O I
10.3389/fonc.2021.646355
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Immunotherapy dramatically changed the treatment landscape of gastric cancer in recent years. PD-L1 expression was proposed as a biomarker; however, the treatment strategy according to PD-L1 is still uncertain. Here, we aimed to find the appropriate cutoff value of PD-L1 expression for gastric cancer immunotherapy.</p> Methods We did a systematic electronic research of prospective clinical trials of gastric cancer immunotherapy across databases. Studies that provided subgroup analysis results stratified by PD-L1 expression were included. Objective response rate (ORR), disease control rate (DCR), hazard ratio (HR), and 95% confidential interval (CI) of progression-free survival (PFS) and overall survival (OS) at different PD-L1 cutoff values were extracted.</p> Results Twelve studies and 6,488 patients in total were finally included for pooled analysis. ORR in allover, PD-L1-negative, combined positive score (CPS) >= 1, CPS >= 5, and CPS >= 10 population was 10%, 3%, 13%, 20%, and 23%, respectively. Immune checkpoint inhibitor (ICI) monotherapy failed to show survival advantage in allover and PD-L1-negative patients. Single-agent ICI therapy prolonged OS (HR = 0.84, 95% CI: 0.74-0.96) but not PFS (HR = 1.38, 95% CI: 0.91-2.09) in PD-L1 CPS >= 1 patients. For combined immunotherapy, ORR in allover, PD-L1-negative, CPS >= 1, CPS >= 5, and CPS >= 10 population was 64%, 57%, 48%, 60%, and 58%, respectively. Allover population could gain survival benefit from combined immunotherapy based on the results from Checkmate-649. OS (HR = 0.81, 95% CI: 0.71-0.92) and PFS (HR = 0.77, 95% CI: 0.69-0.86) were significantly prolonged in PD-L1 CPS >= 1 patients receiving combined immunotherapy.</p> Conclusion Efficacy and survival advantages improved with PD-L1 CPS. CPS >= 1 was the cutoff value for ICI monotherapy to gain survival benefit. Combined immunotherapy prolonged PFS and OS in allover population but needs further study to confirm it.</p>
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
    Liu, Surui
    Gao, Wei
    Ning, Yan
    Zou, Xiaomeng
    Zhang, Weike
    Zeng, Liangjie
    Liu, Jie
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [22] PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis
    Lobrano, Renato
    Paliogiannis, Panagiotis
    Zinellu, Angelo
    Palmieri, Giuseppe
    Persico, Ivana
    Mangoni, Arduino A. A.
    Cossu, Antonio
    [J]. CURRENT ONCOLOGY, 2023, 30 (05) : 5135 - 5144
  • [23] Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis
    Liu, Kewei
    Wang, Dongpo
    Yao, Cong
    Qiao, Min
    Li, Qing
    Ren, Weicong
    Li, Shanshan
    Gao, Mengqiu
    Pang, Yu
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [24] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
    Yang, Yao
    Chen, Dongbo
    Zhao, Bigeng
    Ren, Liying
    Huang, Rui
    Feng, Bo
    Chen, Hongsong
    [J]. CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
  • [25] The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiao-Jiang
    Yuan, Shu-Qiang
    Duan, Jin-Ling
    Chen, Yong-Ming
    Chen, Shi
    Wang, Yun
    Li, Yuan-Fang
    [J]. DISEASE MARKERS, 2020, 2020
  • [26] Correlation between exosomal PD-L1 and prognosis in patients with cancer: a systematic review and meta-analysis
    Huang, Lijun
    He, Qiurong
    Liu, Liping
    Huang, Jie
    Chang, Fan
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [27] Prognostic Role of PD-L1 Expression in Invasive Breast Cancer: A Systematic Review and Meta-Analysis
    Cirqueira, Magno Belem
    Mendonca, Carolina Rodrigues
    Noll, Matias
    Soares, Leonardo Ribeiro
    de Paula Carneiro Cysneiros, Maria Auxiliadora
    Paulinelli, Regis Resende
    Moreira, Marise Amaral Reboucas
    Freitas-Junior, Ruffo
    [J]. CANCERS, 2021, 13 (23)
  • [28] Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis
    Zefeng Shen
    Lihu Gu
    Danyi Mao
    Manman Chen
    Rongjia Jin
    [J]. World Journal of Surgical Oncology, 17
  • [29] The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
    Li, Yan
    He, Meizhi
    Zhou, Yaoyao
    Yang, Chen
    Wei, Shuyi
    Bian, Xiaohui
    Christopher, Odong
    Xie, Lang
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [30] Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis
    Shen, Zefeng
    Gu, Lihu
    Mao, Danyi
    Chen, Manman
    Jin, Rongjia
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2019, 17 (1)